Sign up Australia
Proactive Investors - Run By Investors For Investors

Admedus signs deal to market its heart tissue products in Spain and Portugal

The company recently raised $6 million to expand and progress its strategic projects.
a heart figure
With numerous catalysts on the horizon 2018 could be a watershed year for the company

Admedus Ltd (ASX:AHZ) has signed an exclusive distribution agreement with leading healthcare group, Cardiva, to market and supply its ADAPT® tissue products in Spain and Portugal.

Under the agreement, Cardiva will initially distribute Admedus’ flagship ADAPT® tissue product CardioCel®, a non-calcifying, non-toxic bio-scaffold used to treat congenital heart defect and disease.

Additional ADAPT® products, VascuCel® and CardioCel 3D®, will be added to the Cardiva distribution portfolio later in the year.

Cardiva is a leading company in the Spanish and Portuguese health system, providing physicians access to a wide range of innovative devices in the areas of interventional cardiology, cardiac surgery and pain management.

Admedus chief operating officer David St Denis said: “Through this partnership with Cardiva, Admedus is thrilled to offer our clinically superior ADAPT® products to patients in Spain and Portugal - one of the five largest markets in Europe.

“With first orders due this month, we anticipate demand in this region to grow steadily as more surgeons are introduced to the unique clinical and health benefits of our ADAPT® technology,”

READ: Admedus secures $6 million to expand medical technologies strategy

Earlier this month, Admedus secured commitments to raise about $6 million from institutional and sophisticated investors in a placement at 30 cents per share.

Funds raised will enable the company to expand and progress its strategic projects, including the acceleration of its product portfolio from development to commercialisation.

Admedus has already submitted multiple patent applications in the US as it targets entry into the lucrative TAVR (transcatheter aortic valve replacement) market, currently worth US$3.5 billion and expected to grow to US$5 billion by 2020.

READ: Admedus has healthy mix of reliable Infusion earnings and strong revenue growth from ADAPT

Admedus has also invited existing shareholders to participate in a share purchase plan (SPP).

This offers the opportunity for each shareholder to subscribe for up to $15,000 worth of new Admedus shares by Monday, 28 May 2018 at a price of 30 cents per share.

View full AHZ profile View Profile

Admedus Ltd Timeline

Related Articles

car-t cells definition
September 24 2018
The phase I clinical study will evaluate the safety of MaxCyte's MCY-M11 chimeric antigen receptor in people with relapsed or difficult-to-treat ovarian cancer and peritoneal mesothelioma
lungs
September 25 2018
The drug developer had originally to recruit 80 people for the second part of its phase II study of its SNG001 treatment, but it will now assess 120 patients
immunotherapy graphic
September 13 2018
A clinical trial application for the potential cancer treatment is on track to be filed in the current quarter, and that will be followed by patient recruitment towards the end of the year

© Proactive Investors 2018

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use